Scholarlink

<p>The recent updates to benign prostatic hyperplasia treatment from American (2023) and European (2024) guideline recommend the use of alpha-1 blockers in conjunction with phosphodiesterase-5 inhibitors. A new green mixed micellar liquid chromatographic method was established to concurrently analyze alpha-1 blockers, terazosin/tamsulosin, and tadalafil, a major phosphodiesterase-5 inhibitor. Quality by Design was integrated to enhance essential chromatographic variables and resulted in elevated desirability functions. A comprehensive design space was established, guaranteeing the method's reliability. The separation was carried out on a reversed-phase C18 column (150 × 4.6&#xa0;mm, 5&#xa0;µm) using organic-solvent-free mobile phase consisting of a mixture of Brij-35 (20&#xa0;mM), sodium dodecyl sulfate (150&#xa0;mM), and sodium dihydrogen phosphate buffer (10&#xa0;mM) adjusted to pH 4.84 and flow rate of 1&#xa0;mL/min. Ultraviolet detection was performed at 285&#xa0;nm for tadalafil and 214&#xa0;nm for terazosin and tamsulosin. The linearity range observed for all drugs under investigation was (5–100&#xa0;µg/mL). The limits of detection were 0.27, 0.29, and 0.32&#xa0;µg/mL, and the limits of quantification were 0.81, 0.88, and 0.97&#xa0;µg/mL for terazosin, tadalafil, and tamsulosin, respectively. Validation in accordance with International Council for Harmonisation guidelines was successfully implemented. The approach was effectively utilized to identify analytes in the formulated tablets and pharmaceutical products. The ecological impact of the method was evaluated using the complex green analytical procedure index and Analytical GREEnness metrics, demonstrating the advantages of the proposed procedure over previously reported methods.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

A QbD-based method for the simultaneous determination of tadalafil, terazosin, and tamsulosin using organic-solvent free mixed-micellar HPLC: a sustainable green approach

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年7月1日

查看全文
  • Yahya Bin Abdullah Alrashdi,
  • Galal Magdy,
  • Mohamed M. Osman,
  • Samy G. Alamir,
  • Sami El Deeb,
  • Ahmed Al-Harrasi,
  • Adel Ehab Ibrahim

摘要

The recent updates to benign prostatic hyperplasia treatment from American (2023) and European (2024) guideline recommend the use of alpha-1 blockers in conjunction with phosphodiesterase-5 inhibitors. A new green mixed micellar liquid chromatographic method was established to concurrently analyze alpha-1 blockers, terazosin/tamsulosin, and tadalafil, a major phosphodiesterase-5 inhibitor. Quality by Design was integrated to enhance essential chromatographic variables and resulted in elevated desirability functions. A comprehensive design space was established, guaranteeing the method's reliability. The separation was carried out on a reversed-phase C18 column (150 × 4.6 mm, 5 µm) using organic-solvent-free mobile phase consisting of a mixture of Brij-35 (20 mM), sodium dodecyl sulfate (150 mM), and sodium dihydrogen phosphate buffer (10 mM) adjusted to pH 4.84 and flow rate of 1 mL/min. Ultraviolet detection was performed at 285 nm for tadalafil and 214 nm for terazosin and tamsulosin. The linearity range observed for all drugs under investigation was (5–100 µg/mL). The limits of detection were 0.27, 0.29, and 0.32 µg/mL, and the limits of quantification were 0.81, 0.88, and 0.97 µg/mL for terazosin, tadalafil, and tamsulosin, respectively. Validation in accordance with International Council for Harmonisation guidelines was successfully implemented. The approach was effectively utilized to identify analytes in the formulated tablets and pharmaceutical products. The ecological impact of the method was evaluated using the complex green analytical procedure index and Analytical GREEnness metrics, demonstrating the advantages of the proposed procedure over previously reported methods.